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Summary
Origanum majorana Linn. (Family- Labiatae) is a herb, commonly grows in Mediterranean regions. The plant
has been used in the treatment of diseases related to the nervous system as an antiepileptic and sedative drug in
traditional medicines. In this study, anticonvulsant and sedative activities for different extracts of aerial parts
(leaves and stems) of O. majorana are evaluated. An anticonvulsant effect of O. majorana was investigated
using the Pentylenetetrazole (PTZ) and maximal electroshock (MES) test The pet ether, chloroform, acetone,
methanol and aqueous extracts (PEOM, CEOM, ACEOM, MEOM, and AQEOM respectively) of O. majorana
exhibited anticonvulsant effect in both the PTZ and MES induced seizure models at the doses of 250 and 500
mg/kg, i.p. The extracts of O. majorana delayed the onset of seizures and reduced the duration of seizures in
PTZ test and decreased the duration of seizures in MES test compared to the control group. The CEOM
exhibited maximum reduction (58.47 and 44.83% in PTZ and MES test respectively) in the duration of seizures,
hence it was processed to isolate triterpenoic acid fraction (TAF) which contained substantial amount of ursolic
acid. The TAF exhibited maximum reduction (64.54 and 59.31% in PTZ and MES test respectively) in the
duration of seizures compared to the other extracts of O. majorana. Also, the test extracts decreased the latency
and increased the duration of total sleeping time significantly. The antagonism of chemically and electrically
induced seizures that O. majorana extracts possess anticonvulsant activity. Presence of flavonoids, steroids,
triterpenoids and essential oil may be responsible for the anticonvulsant activity of this plant.
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Introduction

Marjoram, O. majorana is a tender perennial herb of the mint family (Labiatae), which was formerly classified
as Majorana hortensis Moench (Vagi et al,2002). Majorana is a fairly small slightly sprawling, soft grey-green
leafed plant, to 2 feet/ 60 cm (smaller if grown as an annual) with ‘knots’ of fairly insignificant pink or white
flower or weiry erect stems in mild summer. It is widely used in traditional medicines as well as in the food and
cosmetic industries. The herb has carminative, antispasmodic, diaphoretic and diuretic properties (Vagi et al,
2005). In particular sweet marjoram herb contains upto 3% volatile oil, flavonoid glycosides, tannin, steroids
(e.g. ß-sitosterol) and triterpenoids (oleanolic acid and ursolic acid) (Leung et al, 1996). It also contains linalool,
sabinol, terpinen-4-ol, thujanol, camphor, carvacrol, eugenol, pinene, alpha terpenene (Shirley, 1993).The
different extracts of O. majorana possess antioxidant, antimicrobial and antiinflammatory activities (Heo et al,
2002; Deans et al, 1990; Ezzeddine et al, 2001). The herb is used in some parts of Punjab as pot herb like mint.
It is a good general tonic, with carminative, diaphoretic, diuretic, expectorant and stimulant effect (Nadkarni et
al,1999). It has a stronger effect on the nervous system however no experimental evidence reported in the
literature (Chevallier, 1996)
The epilepsy belongs to the most encountered neurological conditions since it affects approximately 1%
of the world population. About 75-80% of epileptic patients may be provided with adequate seizure control with
the help of conventional allopathic antiepileptic drugs. There is therapeutic failure in 20-25% of patients which
stimulated exhaustive research on novel antiepileptic drugs (Piotr et al, 2005). For centuries, herbs have been
used in traditional medicines to treat a wide range of ailments, including central nervous system disorders such
as epilepsy. However, the mechanism of action by which these botanicals exert their therapeutic effects has not
been completely elucidated. Use of O. majorana in the traditional medicine for the treatment of epilepsy and
lack of experimental evidence motivated us to undertake the present investigation.
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Methods

Drugs and chemicals
Pentylenetetrazole was purchased from Sigma-Aldrich chemical company, USA. Diazepam and Phenytoin were
obtained from Ranbaxy, Delhi, India. Sodium pentobarbitone was purchased from BDH chemicals, Kandivli,
Mumbai, India. The solvents and chemicals used were of analytical grade. Ursolic acid standard was received
from Sami Labs Limited, Banglore, India.
Plant material and extraction procedure
The dried aerial parts (leaves and stems) of O. majorana were collected from the local market, Mumbai and
were authenticated by Dr. A. M. Mujumdar, Head Plant science division, at Agharkar Research Institute, Pune,
India, in September 2005. The dried aerial parts of O. majorana were powdered. The powder was extracted
successively with solvents of increasing polarity viz. pet ether (60-80oC), chloroform, acetone, methanol and
water using soxhlet extraction apparatus. The extracts were concentrated under vaccum at (60±50C). The
chloroform extract was processed to get a triterpenoic acid fraction (TAF). The extracts were suspended in 3%
w/v acacia solution before administration to animals.
Fractionation of Triterpenoic acid fraction
The TAF was generated from chloroform extract. In brief, 8 g of dried chloroform extract was dissolved in 40
ml of chloroform, which was subsequently treated with 40 ml of saturated sodium bicarbonate solution twice.
The sodium bicarbonate fractions were separated and pooled. Triterpenoic acids were regenerated by acidifying
the solution with concentrated hydrochloric acid followed by extraction in chloroform. The triterpenoic acids
were obtained by evaporating chloroform under vacuum. The TAF was quantified for ursolic acid using HPTLC
technique.
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Animals
Swiss albino mice of either sex (18-22 g) were used for the present study. Male mice are preferred for the
electroshock test. The animals were housed in standard environmental conditions of temperature (22 ± 50C) and
relative humidity (55 ± 15 %) with 12-h light-dark cycles. They were fed on conventional laboratory pelleted
diet and water ad libitum. All the procedures were performed in accordance with the Committee for the Purpose
of Control and Supervision of Experiments on Animals (CPCSEA) under Ministry of Animal Welfare Division,
Government of India, New Delhi, India (CPCSEA, 2003). The Institutional Ethical Committee and in-charge of
animal house of Sarawathi Vidya Bhavan’s College of Pharmacy, approved the experimental protocol.
Quantification of ursolic acid using HPTLC
Ursolic acid content of the test extracts of O. majorana were determined by HPTLC on 20x20 cm silica gel 60,
F254 (Merck, Germany) plate, using chloroform: methanol (95:5) as the mobile phase and ursolic acid as
reference standard. Application of samples was carried out using Linomat 5 applicator and CAMAG 3
densitometer was used to analyze the plate (λmax-366 nm).
Induction of Convulsive seizures
Pentylenetetrazole (PTZ) induced convulsions
Convulsive seizures were induced by intraperitoneal injection of PTZ (70 mg/kg, i.p.). The mice were divided
into 14 groups of 6 each. Control group received vehicle (0.5 ml of 3% w/v acacia solution), other standard
group received diazepam (10 mg/kg, i.p.) as reference standard and the remaining 12 groups were administered
PEOM, CEOM, ACEOM, MEOM, AQEOM and TAF in doses of 250 and 500 mg/kg, i.p., 30 min prior to the
administration of PTZ. The onset of general clonus was used as the end point. The general clonus was
characterized by fore limb clonus followed by full clonus of the body. The time of onset and duration of clonic
convulsions, and mortality protection were recorded (Vogel et al, 1997). Percentage reduction in duration of
seizures is calculated by considering the duration of seizures in control group as 100%.
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Electroshock induced convulsions
The procedure was carried out as described by Taman (Toman et al,1964) and swinyard et al (Swinyard et
al,1952) The electrical stimulus (50 mA, 0.3 s) was applied 30 minutes after i.p injection of the O. majorana
extracts through ear-clip electrodes using stimulator apparatus (KI 9531, Dolphin, Mumbai, India). Tonic hind
limb extension was considered as the end point. Anticonvulsant activity was evaluated by determining two
parameters viz: the electroconvulsive threshold and percentage reduction in seizure duration by MES test. The
convulsive threshold was determined using electroshocks of various intensities. The convulsive threshold was
determined and the protective effect of test extracts was assessed against maximal electroshock. (50 mA,0.3 s)
induced convulsive seizures.
In both cases, the animals were divided into 14 groups of 6 each, among which the 12 groups of mice were
administered PEOM, CEOM, ACEOM, MEOM, AQEOM and TAF in doses of 250 and 500 mg/kg, i.p. each.
Standard group received phenytoin (20mg/kg i.p.) and control group received vehicle (0.5ml of 3%w/v acacia
solution). The time for the extract to reach the maximum effect was determined as 30 minute after i.p. injection.
The threshold, duration of tonic convulsion and mortality protection were recorded (Hosseinzadeh et al,2003).
Percentage reduction in duration of seizures is calculated by considering the duration of seizures in control
group as 100%.
Statistical analysis
The data were expressed as the mean ±S.E.M. obtained from the number of experiments (n=6). One-way
ANOVA with Dunnett's post test was performed using GraphPad Prism version 4.00 for Windows, GraphPad
Software, San Diego California USA, www.graphpad.com. The Statistical significance was accepted at p<0.05.
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Results

Preliminary phytochemical screening
The preliminary qualitative phytochemical analysis revealed that the extracts of O. majorana contained
flavanoids, triterpenoids and steroids.

HPTLC analysis
In HPTLC analysis, ursolic acid was identified and quantified from each extract having RF value in the range
from 0.4 to 0.45. The plot of the peak area of the ursolic acid Vs concentration (mcg) was straight line shown in
the figure 1. R2=0.9966. The presence of ursolic acid in the extracts is shown in the figure 2 and its percentage
in each extract is mentioned in table 1.
Standard plot of ursolic acid
y = 2166.8x + 3176.9
2
R = 0.9966
16000
14000
12000
Peak area
10000
8000
6000
4000
2000
0
0

2

4

6

Ursolic acid concentration (mcg)

Figure 1 Standard plot of ursolic acid.
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Ursolic
acid

Figure 2: Quantification of ursolic acid in the extracts of O. majorana. (λmax- 366 nm.)
Presence of ursolic acid in the extracts is shown in the figure by arrow.
U1: PEOM, U2: CEOM, U3: ACEOM, S1 to S5 (Concentration grading from 1 to 5 mcg): Ursolic acid
(standard), U4: MEOM, U5: AQEOM, U6: TAF

Table 1: The % w/w of ursolic acid present in O. majorana extracts.
Extracts

(%w/w) Ursolic acid

PEOM

0.9

CEOM

1.13

ACEOM

0.11

MEOM

0.34

AQEOM

-

TAF

1.18
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Effect of O. majorana extracts in PTZ test
The results of the PTZ test are presented in Table 2. In animals treated with vehicle, clonic convulsions
appeared at 78.50±2.69 s after PTZ injection (70 mg/kg, i.p.) and all animals died after seizures. The PEOM,
CEOM, MEOM and TAF delayed the onset of seizures and decreased the duration of seizures significantly
(p<0.05) as compared to the control group. No extract had complete seizure and mortality protective effect but
the CEOM and TAF showed maximum % reduction in the duration of seizures. Diazepam (10 mg/kg i.p.)
inhibited seizures completely.
Table 2: Effect of O. majorana extracts in PTZ-induced seizure in mice.
(%) Mortality
protection

52.17±2.18

(%) Reduction
in duration of
seizure
0

-

-

100

100

250

193.2±2.30**

32.17±2.35**

38.33

33.34

PEOM

500

216.2±2.50**

26.50±3.08**

49.20

50

CEOM

250

231.2±2.82**

26.83±2.05**

48.56

70

CEOM

500

262.5±2.15**

21.67±1.80**

58.47

66.67

ACEOM

250

97.83±2.76**

46.17±1.83*

11.50

16.67

ACEOM

500

104.2±2.38**

43.17±0.94*

17.25

33.34

MEOM

250

139.2±2.52**

35.67±2.24**

31.63

50

MEOM

500

153.5±2.34**

29.17±2.53**

44.09

50

AQEOM

250

111.8±2.38**

42.83±1.79*

17.89

33.34

AQEOM

500

124.2±2.41**

39.50±1.52**

24.28

33.34

TAF

250

270.3±2.64**

23.17±2.00**

55.59

66.67

TAF

500

294.2±3.20**

18.50±1.87**

64.54

66.67

Dose
(mg/kg
i.p.)
-

Onset of
seizure (s)

Duration of
seizure (s)

78.50 ±2.69

Diazepam

10

PEOM

Treatmet
Control

0

Values are expressed as mean ± S.E.M. (n=6), *p<0.05, **P< 0.01 compared to control.
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Effect of O. majorana extracts in MES test
The results of the electroconvulsive threshold and maximal electroshock (50mA, 0.3 s) are showen in Table 3
and 4 respectively. The PEOM, CEOM, MEOM and TAF showed significant change in the electroconvulsive
threshold compared to the control group.
In the MES test the duration of hind limb tonic extension in mice treated with vehicle was 24.17±1.10 s.
The PEOM. CEOM, MEOM and TAF at the dose of 500 mg/kg, i.p. exhibited significant reduction in the
duration of seizures compared to control group. Also, no mortality was observed in case of all the tested extracts
of O. majorana with MES ( 50 mA, 0.3 s).

Discussion
The present study indicated that all the test extracts of O. majorana possess significant anticonvulsant activity
in PTZ and MES induced seizures at 500 mg/kg dose. Maximum reduction in seizure duration was shown by
TAF (64.54 and 59.31 % in PTZ and MES tests respectively). The most popular and widely used animal seizure
models are the traditional MES and PTZ test. The MES test is considered to be a predictor of likely therapeutic
efficacy against generalized tonic-clonic seizures. By contrast PTZ test represents a valid model for human
generalized myoclonic seizures and also generalized seizures of petit mal (Loscher et al,1998). Thus, our results
suggest the O. majorana extracts may be effective against human generalized myoclonic seizures and also
absence ones. PTZ a chemoconvulsant is reported to induce seizures by depressing chloride channel function by
binding to picrotoxin site on the Gamma amino butyric acid (GABA) receptor complex (Kulkarni et al, 1993). It
has been indicated that PTZ induced seizures can be prevented by drugs that enhance GABAA receptormediated inhibitory neurotransmission (Rogawski et al, 1995; Macdonald et al, 1995).

Preliminary

phytochemical analysis performed in this study showed that terpenoids, steriods and flavonoids are the major
components of O. majorana extracts.
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Table 3: Effect of O. majorana extracts on the threshold of electroshock induced seizure in mice.
Dose (mg/kg,
Treatment

Electroconvulsive threshold (mA)
i.p.)

Control

-

9.50±0.50

Phenytoin

20

21.50±0.61**

PEOM

250

13.00±1.00*

PEOM

500

13.50±0.67**

CEOM

250

13.50±0.71**

CEOM

500

13.50±1.02**

ACEOM

250

10.00±0.63

ACEOM

500

12.50±0.92

MEOM

250

12.00±0.77

MEOM

500

13.00±0.63*

AQEOM

250

11.50±1.20

AQEOM

500

12.00±1.09

TAF

250

13.00±0.57*

TAF

500

14.50±0.50**

Values are expressed as mean ± S.E.M. (n=6), *p<0.05, **P< 0.01 compared to
control
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Table 4: Effect of O. majorana extracts in MES-induced seizure in mice.
Dose (mg/kg,
Treatment

(%) Reduction in
Duration of seizure (s)

i.p.)
Control

duration of seizure

-

24.17±1.10

0

Phynetoin

20

7.16±1.18**

70.37

PEOM

250

17.33±1.43*

28.28

PEOM

500

15.67±1.54**

35.17

CEOM

250

15.83±1.16**

34.48

CEOM

500

13.33±0.71**

44.83

ACEOM

250

18.83±1.40*

22.07

ACEOM

500

18.17±1.22*

24.83

MEOM

250

18.17±1.57*

26.21

MEOM

500

15.50±1.28**

35.86

AQEOM

250

18.67±1.54*

22.76

AQEOM

500

17.37±1.36*

28.14

TAF

250

12.83±1.30**

46.90

TAF

500

9.83±0.94**

59.31

Values are expressed as mean ± S.E.M. (n=6), *p<0.05, **P< 0.01 compared to control
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It is reported that anticonvulsant activity of terpene SL-1, a synthetic monoterpene homologue of
GABA, demonstrated anticonvulsant activity in PTZ induced seizures (Librowski et al,2000). Linnalool is
another terpene compound which has protective effect against PTZ induced seizures (Silva Brum et al, 2001).
Moreover pinene, eugenol and methyleugenol exhibited anticonvulsant profile in some experimental seizures
such as MES and PTZ tests (Consroe et al,1981; Dallmeier et al, 1981).
Modulation of glutaminergic and gabaminergic transmission is one of the possible mechanisms
indicated for anticonvulsant action of the terpenes like linalool and eugenol (Wie et al, 1981). Hence, it is
possible that the anticonvulsant effects of O. majorana may be related in part to terpenes and terpenoid
compounds present in the extracts.
The mechanism of anticonvulsant activity of the extracts is not clear. The quantity of ursolic acid
present in all extracts is revealed by HPTLC analysis. TAF showed good anticonvulsant activity as it contains
more amount of ursolic acid (1.18 %w/w of TAF) compared to the test extracts. Ursolic acid has been reported
to have some effect on CNS. In a study, it was demonstrated that the ursolic acid of O. majorana appeared to be
a potent acetyl cholinesterase inhibitor in Alzeimer’s Disease (Yo-Kyung Chung et al, 2001). As Alzeimer’s
disease is related to CNS, it is possible that the ursolic acid may be responsible for the anticonvulsant activity of
O. majorana extracts.
The results of the study revealed that O. majorana has potential anticonvulsant activity. However
detailed experimental studies should be performed to elucidate the mechanism of action and to support this
suggestion. The constituents like terpenoids and ursolic acid can be further explored to be the probable active
constituents.
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LIST OF NON-STANDARD ABBREVIATIONS
PEOM: Pet ether extract of O. majorana
CEOM: Chloroform extract O. majorana
ACEOM: Acetone extract O. majorana
MEOM: Methanol extract O. majorana
AQEOM: Aqueous extract O. majorana
TAF: Triterpenoic acid fraction
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